Viridian Therapeutics Inc.

4 days ago · seekingalpha.com

Viridian Therapeutics shifts focus from regulatory risk to launch execution after FDA approval of Lumvoa for thyroid eye disease (TED). VRDN aims to leverage its commercial infrastructure for both Lumvoa and investigational elegrobart, potentially improving franchise economics and operational efficiency. The current valuation is demanding, with no near-term asset-based floor; future profitability hinges on successful commercialization and infrastructure sharing.

14 days ago · globenewswire.com

OTTAWA, Ontario, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (OTCQB: VIRMF) reports initial assay results from its 2026 drill program at the Kraken Main Zone in Labrador.

20 days ago · businesswire.com

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 12:45pm ET. A live webcast of the fireside chat can be accessed under “Events and Presentations” on the Invest.

2 months ago · globenewswire.com

OTTAWA, Ontario, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Assays are now pending from the first diamond drill holes completed as part of Viridian Metals Inc.'s (CSE: VRDN) (OTCQB: VIRMF) 2026 drill program at the Kraken project in Labrador. The initial assay submission includes the extension of hole VKS25-024, which previously returned 24.05 metres grading 0.77% CuEq¹ (0.21% Cu, 0.30% Ni, 0.04% Co) from 1 metre before terminating in mineralization (see Viridian news release dated February 26, 2025).

2 months ago · businesswire.com

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026. “We are very encouraged by the early indications from our recent launch of Lumvoa as we start a new chapter for Viridian as a commercial-stage company,” said Steve.

3 months ago · zacks.com

Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.

3 months ago · seekingalpha.com

Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen's Tepezza in thyroid eye disease. Lumvoa's shorter infusion course, inclusion of chronic TED data, and immediate availability position VRDN for commercial success, though management is tempering near-term revenue expectations. Elegrobart's underwhelming REVEAL-1 phase 3 results limit its competitive edge in active TED but highlight its convenience and potential in underpenetrated chronic TED based on REVEAL-2 study results.

3 months ago · seekingalpha.com

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript

3 months ago · businesswire.com

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disease characterized by inflammation and tissue remodeling around and behind the.

3 months ago · seekingalpha.com

Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript